Disclaimer: This is educational information about a prescription medication used in testosterone replacement therapy. Testosterone cypionate is a controlled substance in the UK (Class C, Misuse of Drugs Act 1971). It requires a prescription from a licensed medical practitioner. This article does not constitute medical advice.
What Testosterone Cypionate Is
Testosterone cypionate is an esterified form of testosterone. The cypionate ester — a chain of carbon atoms attached to the testosterone molecule — controls how slowly the compound is released after injection. Without an ester, testosterone injected into muscle would be active within hours and clear the system within 24–48 hours. The cypionate ester extends this to a half-life of approximately 8–12 days.
It is the most widely prescribed injectable testosterone in the United States and increasingly the preferred choice of UK private TRT clinics, which have moved away from NHS-default protocols (Nebido, Sustanon) toward the more stable blood level profile that cypionate provides.
Chemical name: Testosterone 17β-cypionate Molecular formula: C₂₇H₄₀O₃ Molecular weight: 412.6 g/mol Half-life: 8–12 days Active life: 14–16 days Detection time: Approximately 3 months
Pharmacokinetics: How It Works in the Body
The Ester Mechanism
After subcutaneous or intramuscular injection, testosterone cypionate forms a depot in the tissue. The ester bond is cleaved by esterases (enzymes in muscle and plasma), releasing free testosterone into the circulation. The rate of ester cleavage determines the release profile.
The cypionate ester produces a peak testosterone level approximately 24–48 hours after injection, followed by a gradual decline over 7–14 days. This is the "peak-to-trough" pattern fundamental to injectable TRT management.
Peak-to-trough ratio is the ratio between the highest and lowest testosterone levels between injections. With once-weekly injection of 100mg testosterone cypionate, typical peak might be 28–32 nmol/L at 24–48 hours post-injection, with trough falling to 14–18 nmol/L at day 6–7 before the next injection. This represents a peak:trough ratio of approximately 2:1.
Injecting more frequently (twice weekly, same total dose) compresses this ratio — peak to trough becomes approximately 1.5:1. More stable blood levels mean more consistent symptom management and easier oestradiol control.
Bioavailability
Injectable testosterone is nearly 100% bioavailable (bypasses first-pass liver metabolism, unlike oral testosterone). This makes injectable forms significantly more efficient per milligram than oral preparations.
Conversion Pathways
Once released as free testosterone, the standard androgenic pathways apply:
Aromatisation to oestradiol: Via aromatase enzyme in fat tissue, liver, brain. Approximately 0.3% of testosterone is converted to oestradiol per day under baseline conditions. With elevated testosterone on TRT, total oestradiol production increases proportionally. Men with more adipose tissue have higher aromatase activity and produce more oestradiol per unit of testosterone.
5-alpha reduction to DHT: Via 5-alpha reductase (type 1 and 2) in skin, prostate, scalp, liver. DHT is 3–5× more androgenic than testosterone at the androgen receptor. DHT rises proportionally with testosterone on TRT. Finasteride/dutasteride will suppress DHT elevation if hair protection is a concern.
Testosterone Cypionate vs. Other Esters
vs. Testosterone Enanthate
The most common comparison. Enanthate has a half-life of 7–10 days (slightly shorter than cypionate's 8–12 days). In practice, the difference is negligible — they are essentially interchangeable for TRT purposes. Both produce very similar blood level profiles when injected weekly. Some TRT clinics use one or the other based on availability and preference.
vs. Sustanon 250 (NHS Default)
Sustanon contains four testosterone esters mixed together: propionate (fast), phenylpropionate (medium), isocaproate (medium-long), and decanoate (long). The fast esters produce an early testosterone spike before the longer esters sustain the level.
The problem: the fast-ester spike means oestradiol spikes acutely in the days after each injection, often producing symptoms (water retention, mood changes, libido fluctuations) even if average oestradiol is acceptable. The longer injection interval of NHS Sustanon protocols (every 2–3 weeks) compounds this variability.
Testosterone cypionate/enanthate at weekly or twice-weekly frequency produces significantly more stable levels and easier oestradiol management than Sustanon at fortnightly intervals.
vs. Nebido (Testosterone Undecanoate)
Nebido is a 1000mg injection every 10–14 weeks. The advantage — very infrequent injections. The disadvantage — the extended release profile makes fine-tuning extremely difficult. If the dose isn't right, you're managing that for 10+ weeks before the next injection. Oestradiol management is harder. Peak-to-trough ratio is substantial.
Nebido is convenient for some men but not optimal for hormonal stability. Most private TRT clinics have moved away from it as a first-line option.
vs. Testosterone Propionate
Propionate has a half-life of approximately 2–3 days, requiring injections every 2–3 days for stable levels. Provides very stable, controllable levels but the injection frequency is impractical for most men. Used historically in competitive contexts where rapid dose adjustment is needed. Not appropriate as a primary TRT preparation for most men.
Dosing Protocols
Standard TRT Dosing
Starting dose: 100mg per week is the standard starting point for most TRT protocols in UK private practice.
Rationale: 100mg/week of testosterone cypionate typically raises total testosterone to 18–25 nmol/L at steady state (reached after approximately 5 half-lives, or 5–6 weeks). This is within the upper half of the physiological range for most men — functional, without being supraphysiological.
Dose adjustment: Based on 6–8 week bloodwork (trough measurement — taken 48 hours before next injection or at the lowest point of the injection cycle).
- Trough testosterone below 15 nmol/L with symptoms: increase to 120–125mg/week
- Trough testosterone 15–25 nmol/L: likely optimal range for most men
- Trough testosterone above 30 nmol/L: consider reducing dose
Twice-weekly protocol (recommended): Split 100mg/week into 50mg twice weekly (Monday/Thursday, or Tuesday/Saturday etc.). Same total testosterone dose — more stable blood levels, lower peak, higher trough, easier oestradiol management.
Higher Dose Considerations
Above 150–175mg/week, testosterone levels become supraphysiological in most men. At this range:
- Haematocrit elevation becomes more pronounced and requires more frequent monitoring
- Oestradiol elevation is more significant — AI consideration becomes more relevant
- The risk:benefit ratio for a pure TRT (quality-of-life) indication shifts
Doses above 175mg/week are generally outside the TRT indication and move toward performance enhancement territory. The clinical and legal considerations shift accordingly.
Administration
Subcutaneous vs. Intramuscular
Intramuscular (IM): Traditional route. Injected into the glute (ventroglute or dorsal glute), quad (vastus lateralis), or deltoid (for small volumes). Absorbed slightly faster than subcutaneous, somewhat higher peak-to-trough ratio.
Subcutaneous (SubQ): Into the belly fat. 29–31 gauge insulin-type needle, 12.5mm length. Slower absorption, flatter peak-to-trough profile, lower oestrogen spikes. Significant advantages for oestrogen management. Much easier and less painful than IM — this is why most UK private TRT clinics now default to subcutaneous injection protocols.
Current best practice: SubQ, 29-gauge insulin needle, belly or love handle area, twice weekly.
Needle and Volume
- SubQ: 29 or 30 gauge, 12.5mm needle, maximum 0.5ml per site
- IM: 23 or 25 gauge, 25mm needle for most body sites
- For twice-weekly 50mg doses: typically 0.25ml per injection (200mg/ml concentration) or 0.5ml (100mg/ml concentration)
Injection Sites and Rotation
Rotate injection sites to prevent subcutaneous nodule formation. Common rotation: alternate sides (left belly, right belly), or belly area systematically across quadrants. Avoid repeatedly injecting the same spot — this causes lipohypertrophy (fatty tissue nodule) over time.
What to Expect: Phase-by-Phase
Weeks 1–4 (Onset)
Testosterone rising from baseline toward steady state. Early responders notice:
- Improved energy and motivation (often weeks 2–3)
- Better morning erections
- Initial water retention as oestradiol rises alongside testosterone
- Possible mild acne onset (temporary, usually resolves)
Steady state is not reached until approximately week 5–6 (five half-lives). Don't adjust dose before steady state.
Weeks 6–8 (Steady State — First Bloods)
First bloodwork at trough. Assess: total testosterone (trough value), oestradiol, haematocrit. Dose adjustment if needed.
Most symptom improvement is apparent by now — energy, libido, mood, and body composition changes beginning. Body composition changes (muscle retention, fat reduction) are slower — expect 3–6 months for meaningful visible changes.
Months 3–6 (Stabilisation)
Protocol stabilised, dose optimised, oestradiol managed. Benefits compound:
- Body composition improvement becomes visible
- Libido stable and improved
- Energy consistent (not fluctuating with injection cycle)
- Mental clarity and motivation improved
Regular monitoring: haematocrit at 3 months (erythrocytosis risk), PSA baseline for men over 45.
Months 6–12 (Long-term optimisation)
Fine-tuning. Some men require small protocol adjustments as the body adapts. Others remain stable on starting dose. Annual monitoring thereafter.
Monitoring: What to Test and When
Before Starting TRT
- Full hormone panel: total testosterone, SHBG, free testosterone (calculated), LH, FSH, oestradiol, prolactin
- PSA (men over 40–45)
- Haematocrit and full blood count
- Liver function
- Thyroid (TSH, Free T3, Free T4)
- Vitamin D, HbA1c
At 6–8 Weeks (Trough)
- Total testosterone (trough — 48 hours before next injection)
- Oestradiol
- Haematocrit
- Symptom assessment
At 3 Months
- Full panel repeat
- Haematocrit (primary safety marker — target below 52%)
- PSA (baseline comparison)
Ongoing (Every 3–6 Months)
- Testosterone, oestradiol, haematocrit, PSA
- Annual: full metabolic panel, liver function, thyroid
The Haematocrit Imperative
Haematocrit above 52–54% significantly increases blood viscosity and cardiovascular risk (stroke, DVT, PE). This is the primary safety monitoring parameter on TRT.
Management if elevated:
- Increase injection frequency (same dose, more frequent = lower peak haematocrit stimulation)
- Stay well-hydrated
- Blood donation (UK NHS allows donation; disclose TRT to the Blood Service)
- Consider dose reduction if persistent
Oestrogen Management
As covered in the anastrozole guide — manage with dose adjustment first, AI second if genuinely indicated.
Oestradiol target on TRT: 80–130 pmol/L symptomatic range. Values up to 160–180 pmol/L are often well-tolerated. Symptoms guide management more than absolute numbers.
Subcutaneous injection advantage: SubQ administration produces a flatter absorption curve, lower oestradiol peaks, and often eliminates the need for an AI entirely — even for men who required one on IM protocols.
Risk Profile
Erythrocytosis (elevated haematocrit): The most clinically significant risk. Manageable with monitoring and donation.
Cardiovascular: The relationship between TRT and cardiovascular risk is nuanced. Multiple observational studies show improved cardiovascular outcomes with TRT in hypogonadal men. The primary concern is erythrocytosis-driven increased viscosity. Men with pre-existing significant cardiovascular disease should have TRT carefully assessed by a cardiologist.
Prostate: TRT does not cause prostate cancer. This is the most persistent myth in men's health. Men with existing untreated prostate cancer are contraindicated. Men with well-controlled prostate conditions should discuss individual risk with their urologist. Annual PSA monitoring is appropriate for men over 45.
Fertility: TRT suppresses sperm production via HPG axis suppression. Men who want biological children should delay TRT or use HCG co-treatment. See the enclomiphene guide for the alternative approach.
Polycythaemia: In some men with the genetic predisposition, haematocrit rises significantly on even modest TRT doses. Monitoring is essential; therapeutic phlebotomy (blood donation) is effective management.
The Short Version
Testosterone cypionate is the gold standard injectable testosterone for TRT. Half-life 8–12 days. Standard TRT dose 100–125mg per week, split twice weekly subcutaneously for best stability and oestrogen management. Steady state at 5–6 weeks. Key monitoring: trough testosterone, oestradiol, haematocrit. Primary risk is erythrocytosis — manageable with monitoring and donation. Most long-term data supports cardiovascular benefit in genuinely hypogonadal men. Fertility is suppressed — manage with HCG or enclomiphene if relevant.